RxDoctor Payments Data

Edward Cheng, MD

Clinical Cardiac Electrophysiology · Gresham, ORNPI 1417360587

Payments from drug & device makers

What this record shows

This record is dominated by grants: $26,844 of the $38,976 with a category attached, or 68.9%. 26 manufacturers reported payments, led by Boston Scientific at 45.8% of the total. Reporting peaked in 2021 at $14,580 and has fallen 97.4% since, to $375 in 2025.

$38,976in general payments, 2019–2025

Across 341 payments — averaging $114.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$18K
  • Medtronic$15K
  • Abbott$3K
  • Medical Device Business Services, Inc.$752
  • Biosense Webster, Inc.$614
  • Cvrx, Inc.$267
  • plus $1K from 20 others

What the payments were for

  • Grants$26,84469%
  • Travel & lodging$3,5509%
  • Food & beverage$8,42522%
  • Education$1580%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,976 in reported general payments places this provider in the 85th percentile of 37 clinical cardiac electrophysiology providers in Oregon.

See all clinical cardiac electrophysiology providers in Oregon

Medicare billing

Part B allowed, 2024
$157,797
Medicare patients
706
Services billed
1,970

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban226$261,178
MultaqDronedarone Hcl25$40,890
XareltoRivaroxaban21$28,378
Ranolazine ErRanolazine58$5,319
Mexiletine Hcl48$4,476
Dofetilide25$3,087
Metoprolol Succinate215$2,775
Flecainide Acetate25$1,497
Amiodarone Hcl129$1,231
Colchicine72$1,058
SotalolSotalol Hcl42$894
Diltiazem 24hr Er (Cd)Diltiazem Hcl19$803
Potassium Chloride26$706
Pantoprazole Sodium63$650
Torsemide21$564

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$71$261,178226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 37 clinical cardiac electrophysiology providers in Oregon.

Other clinical cardiac electrophysiology in Gresham

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →